Septarna Inc. (SEPN)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?
15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share. This transaction impacted 13.46% of Long's direct Common Stock holdings, reducing his position to 96,412 shares.
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.49 per share a year ago.
Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.64 per share a year ago.
Septerna's Novo Partnership Begins To Transform The Story
Septerna, Inc. delivered a strong 3Q25, driven by partnership revenue from its transformative collaboration with Novo Nordisk. SEPN's Novo partnership brings $195M upfront, a potential $2.2B in milestones, and full R&D funding, reducing capital burden and boosting strategic position. The incretin-pathway GPCR program is closest to early milestones, with further upside tied to successful target validation and hit-to-lead advancements.
Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates
Septerna, Inc. (SEPN) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of $0.19. This compares to a loss of $8.4 per share a year ago.
Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength?
Septerna, Inc. (SEPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist
Septerna's partnership with Novo Nordisk is a strong endorsement, but the $195m upfront is modest (by Big Pharma standards) and milestone payments are not guaranteed. The company's innovative GPCR platform and deep pipeline are promising, yet early clinical setbacks and fierce competition raise execution risks. Septerna's cash position is solid for now, but future clinical expenses may require additional funding, potentially diluting current shareholders.
Wall Street Analysts Predict a 207.31% Upside in Septerna, Inc. (SEPN): Here's What You Should Know
The mean of analysts' price targets for Septerna, Inc. (SEPN) points to a 207.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Septerna halts Phase 1 hypoparathyroidism trial, shares plummet
Septerna (NASDAQ:SEPN) shares tumbled more than 60% after the clinical-stage biotechnology firm announced it is halting its Phase 1 clinical trial of SEP-786 targeting hypoparathyroidism. The company said it chose to discontinue the trial due to the occurrence of elevated bilirubin levels in trial participants.
Goldman-backed drug developer Septerna targets $743 mln valuation in upsized US IPO
Goldman Sachs-backed drug developer Septerna said on Thursday it was seeking a valuation of $743.1 million in its upsized initial public offering in the United States.
Biotech Septerna aims to raise up to $186 million in US IPO
Biotechnology company Septerna said on Monday it is aiming to raise up to $186 million in its initial public offering in the United States.
